Related Experiment Video
Updated: May 26, 2026
04:40
Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
[Cancer and venous thromboembolism]
1Service de Pneumologie, Université Paris Descartes, Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 20, rue Leblanc 75015 Paris, France. guy.meyer@egp.aphp.fr
Journal Des Maladies Vasculaires
|December 20, 2011
Summary
Cancer patients frequently experience venous thrombo-embolism due to tumor cells activating coagulation. Prophylactic treatments and low-molecular weight heparin show promise in reducing thrombosis and potentially improving cancer survival.
Area of Science:
- Oncology
- Hematology
- Clinical Medicine
Context:
- Cancer and venous thrombo-embolism (VTE) share a frequent clinical association.
- Tumor cells activate the coagulation cascade, increasing thrombosis risk.
- Surgery, chemotherapy, and antiangiogenic agents further elevate VTE risk in cancer patients.
Purpose:
- To review the current understanding of cancer-associated thrombosis (CAT).
- To discuss risk factors, prophylactic strategies, and treatment of VTE in cancer patients.
- To explore the potential direct anti-tumor effects of low-molecular weight heparin (LMWH).
Summary:
- Systematic cancer screening after unexplained thrombosis lacks proven clinical benefit.
- Identified risk factors specific to the cancer population aid in risk stratification.
- Prophylactic treatment with LMWH may reduce VTE incidence in cancer patients, requiring further confirmation.
- Treatment of VTE in cancer patients typically involves 3-6 months of LMWH.
- Experimental data suggest LMWH may enhance cancer patient survival via direct effects on tumor biology.
Impact:
- Highlights the need for confirmed evidence on prophylactic treatments for VTE in cancer.
- Suggests potential survival benefits of LMWH beyond anticoagulation in cancer patients.
- Underscores ongoing clinical trials investigating LMWH's direct anti-tumor effects and impact on survival.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...